Skip to main content

Prescription Drug Prices: Analysis of Canada's Patented Medicine Prices Review Board

HRD-93-51 Published: Feb 17, 1993. Publicly Released: Feb 22, 1993.
Jump To:
Skip to Highlights

Highlights

Pursuant to a congressional request, GAO: (1) described the purpose and structure of Canada's Patented Medicine Prices Review Board as well as its guidelines and procedures, especially those used to determine if a drug price is excessive; and (2) summarized the evidence about the effects of the Board's actions on the prices of new drugs, on price increases for existing drugs, and on pharmaceutical research and development.

Full Report

Media Inquiries

Sarah Kaczmarek
Managing Director
Office of Public Affairs

Public Inquiries

Topics

Comparative analysisCost analysisDrugsForeign governmentsHealth care cost controlPharmaceutical industryPharmacological researchPrice fixingPrice regulationResearch and development costs